logo
California reports sharp rise in Valley fever cases for first three months of 2025

California reports sharp rise in Valley fever cases for first three months of 2025

Yahoo25-04-2025

California is heading toward another record year for cases of Valley fever, the disease caused by fungal spores linked to cycles of drought and precipitation.
There were 3,123 reported cases of Valley fever in the first three months of the year, according to state health officials — roughly double the 10-year average for the first-quarter time period. Cases ranged from a low of 801 in 2016 to 3,011 last year.
Most people who are infected with the fungus won't experience symptoms, and their bodies will fight off the infection naturally. Those who do suffer symptoms however are often hard-pressed to recognize them, as they resemble the onset of COVID or the flu, further complicating efforts to address the disease.
The disease is caused by inhaling spores of coccidioides, a fungal pathogen that thrives in the drier and dustier regions of the state. The fungus is released when the dry soil where it grows is disturbed.
"We actually had sort of seen this coming, just based on the climate cycle of the last few years," said George R. Thompson, a professor of medicine at the UC Davis School of Medicine and a specialist in invasive fungal infections.
Research has shown that patterns of drought and precipitation play important roles in the number of Valley fever cases in California, said Doua Ge Yang, a spokeswoman for the state's Department of Public Health. "When there are several years of drought in California, followed by a wet winter, and then a dry summer," there are increases in the Valley fever cases for the following two years.
She said 2023 typified such a scenario, and as predicted, 2024 resulted in a record-high case count, with 12,637 cases recorded.
"Valley fever is on the rise in California," she said.
While the numbers for 2025 are so far higher than any previously recorded first quarter, Yang said health officials can't predict whether it will remain a record year. She also noted that all the numbers from 2024 and 2025 are considered preliminary — and therefore demographic issues such as age, sex and race cannot yet be reported.
In addition to patterns of rain and drought, research shows that other factors can play a role in incidents of Valley fever — including soil disturbance, such as the kind accompanying construction activity, wild fires and even archaeological digs.
Construction workers, firefighters and archaeologists working in the dry, arid regions of the state are at increased risk of getting the disease — especially as Californians move into these once less inhabited regions of the state.
Last year, at least 19 people who attended Lightning in a Bottle, a five-day music and art festival held at Buena Vista lake in Kern County, succumbed to the disease — including several who reported severe disease, which included pneumonia-like symptoms, rashes, headaches and exhaustion.
The festival's organizers will be holding the event again this year at the same location. According to the festival website, organizers will try to reduce dust by applying water to the ground to keep it in place, adding artificial turf in front of the stages for dancing, and reducing the number of motorized vehicles used by staff around the site, and placing additional wood chips over heavy traffic areas to suppress dust.
Because most people clear the disease on their own, the true number of infected people is not known. However, if a person's immune system is unable to clear the disease, and it is left untreated, it can cause death or permanent disability.
Treatment varies depending upon severity, but antifungal drugs, such as fluconazole (Diflucan) or itraconazole (Sporanox, Tolsura), are the most common medications. However, they come with serious side effects, such as nausea, vomiting, diarrhea, hair loss, dry skin, dry mouth and chapped lips.
While several Central and Southern California counties have seen recent increases in their case counts, Monterey's numbers have ballooned.
In 2023, there were 22 cases reported during the first quarter in the Central California county; this year, the number is 217.
County health officials said they began seeing a surge in November of last year, at which point they sent out a health advisory to local medical providers and clinics providing information about the disease and testing guidance.
Monterey County spokeswoman Karen Smith said that many residents had experienced severe disease and delays in their treatment and diagnosis. She said rates were highest for people who live in the southern part of the county and in the largely agricultural Salinas Valley.
She said the county encourages people to reduce their risk of getting the disease by avoiding breathing in dirt and dust.
Thompson, the UC Davis doctor and researcher, said there has been anecdotal evidence that the disease may be increasing in severity, and there are concerns that it may also have acquired some immunity to the common antifungal medicines used to fight it.
The theory is that the widespread use of antifungal chemicals on crops in areas where the fungus is endemic may be contributing to its resistance, but that research on the topic is only just getting underway, and answers so far are elusive.
He said there's a statewide effort looking into these issues, that includes participation from the U.S. Centers for Disease Control and Prevention, the state's public health department, UC Davis, UC San Francisco, and Cal State Fresno and Cal State Bakersfield.
He said for years the disease had largely been sidelined in public health circles as attention and funding was targeted at other pathogens that had wider and more severe impacts.
"I hate to disparage that, but I think with limited resources, public health agencies do have to really prioritize certain pathogens," he said.
This story originally appeared in Los Angeles Times.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance
Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance

Yahoo

timean hour ago

  • Yahoo

Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance

WASHINGTON (AP) — There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a 58-second video that the government would no longer endorse the COVID-19 vaccine for healthy children or pregnant women. The director of the Centers for Disease Control and Prevention — the person who typically signs off on federal vaccine recommendations — was nowhere to be seen. The CDC, a $9.2 billion-a-year agency tasked with reviewing life-saving vaccines, monitoring diseases and watching for budding threats to Americans' health, is without a clear leader. 'I've been disappointed that we haven't had an aggressive director since — February, March, April, May — fighting for the resources that CDC needs,' said Dr. Robert Redfield, who served as CDC director under the first Trump administration and supported Kennedy's nomination as the nation's health secretary. $9.2 billion-a-year agency without leader as nomination awaits The leadership vacuum at a foremost federal public health agency has existed for months, after President Donald Trump suddenly withdrew his first pick for CDC director in March. A hearing for his new nominee — the agency's former acting director Susan Monarez — has not been scheduled because she has not submitted all the paperwork necessary to proceed, according to a spokesman for Sen. Bill Cassidy, R-La., who will oversee the nomination. HHS did not answer written questions about Monarez's nomination, her current role at the CDC or her salary. An employee directory lists Monarez, a longtime government employee, as a staffer for the NIH under the Advanced Research Projects Agency for Health. Redfield described Kennedy as 'very supportive' of Monarez's nomination. Instead, a lawyer and political appointee with no medical experience is 'carrying out some of the duties' of director at the agency that for seven decades has been led by someone with a medical degree. Matthew Buzzelli, who is also the chief of staff at the CDC, is 'surrounded by highly qualified medical professionals and advisors to help fulfill these duties as appropriate,' Andrew Nixon, an HHS spokesperson said in a statement. Adding to the confusion was an employee-wide email sent last week that thanked 'new acting directors who shave stepped up to the plate." The email, signed by Monarez, listed her as the acting director. It was was sent just days after Kennedy said at a Senate hearing that Monarez had been replaced by Buzzelli. The lack of a confirmed director will be a problem if a public health emergency such as the COVID-19 pandemic or a rapid uptick in measles cases hits, said Michael Osterholm, an epidemiologist at the University of Minnesota. 'CDC is a crisis, waiting for a crisis to happen,' said Osterholm. 'At this point, I couldn't tell you for the life of me who was going to pull what trigger in a crisis situation." An acting director rarely seen, and stalled decisions At CDC headquarters in Atlanta, employees say Monarez was rarely heard from between late January – when she was appointed acting director – and late March, when Trump nominated her. She also has not held any of the 'all hands' meetings that were customary under previous CDC chiefs, according to several staffers. One employee, who insisted on anonymity because they were not authorized to speak to the media and fears being fired if identified said Monarez has been almost invisible since her nomination, adding that her absence has been cited by other leaders as an excuse for delaying action. The situation already has led to confusion. In April, a 15-member CDC advisory panel of outside experts met to discuss vaccine policy. The panel makes recommendations to the CDC Director, who routinely signs off on them. But it was unclear during the meeting who would be reviewing the panel's recommendations, which included the expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. HHS officials said the recommendations were going to Buzzelli, but then weeks passed with no decision. A month after the meeting ended, the CDC posted on a web site that Kennedy had signed off on recommendations for travelers against chikungunya, a viral disease transmitted to humans by mosquitos. But there continues to be no word about a decision about the other vaccine recommendations. Controversial COVID-19 vaccine recommendations bypassed CDC panel The problem was accentuated again last week, when Kennedy rolled out recommendations for the COVID-19 vaccine saying they were no longer recommended for healthy children or pregnant women, even though expectant mothers are considered a high-risk group if they contract the virus. Kennedy made the surprise announcement without input from the CDC advisory panel that has historically made recommendations on the nation's vaccine schedule. The CDC days later posted revised guidance that said healthy kids and pregnant women may get the shots. Nixon, the HHS spokesman, said CDC staff were consulted on the recommendations, but would not provide staffer's names or titles. He also did not provide the specific data or research that Kennedy reviewed to reach his conclusion on the new COVID-19 recommendations, just weeks after he said that he did not think 'people should be taking medical advice' from him. 'As Secretary Kennedy said, there is a clear lack of data to support the repeat booster strategy in children,' Nixon said in a statement. Research shows that pregnant women are at higher risk of severe illness, mechanical ventilation and death, when they contract COVID-19 infections. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. Vaccinations also have been recommended for pregnant women because it passes immunity to newborns who are too young for vaccines and also vulnerable to infections. Nixon did not address a written question about recommendations for pregnant women. Kennedy's decision to bypass the the advisory panel and announce new COVID-19 recommendations on his own prompted a key CDC official who works with the committee – Dr. Lakshmi Panagiotakopoulos – to announce her resignation last Friday. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in an email seen by an Associated Press reporter. Signs are mounting that the CDC has been 'sidelined' from key decision-making under Kennedy's watch, said Dr. Anand Parekh, the chief medical adviser for The Bipartisan Policy Center. 'It's difficult to ascertain how we will reverse the chronic disease epidemic or be prepared for myriad public health emergencies without a strong CDC and visible, empowered director,' Parekh said. 'It's also worth noting that every community in the country is served by a local or state public health department that depends on the scientific expertise of the CDC and the leadership of the CDC director.'

MRNA, Used in Covid Shots, May Help Rid the Body of H.I.V.
MRNA, Used in Covid Shots, May Help Rid the Body of H.I.V.

New York Times

timean hour ago

  • New York Times

MRNA, Used in Covid Shots, May Help Rid the Body of H.I.V.

The technology that powered Covid vaccines may also lead scientists to a cure for H.I.V. Using mRNA, Australian researchers said they were able to trick the virus to come out of hiding, a crucial step in ridding the body of it entirely. The research, published last week in Nature Communications, is still preliminary, and so far, has been shown to be successful only in a lab. But it suggests that mRNA has potential far beyond its use in vaccines as a means to deliver therapies against stubborn adversaries. Short for messenger RNA, mRNA is a set of instructions for a gene. In the case of Covid vaccines, the instructions were for a piece of the coronavirus. In the new study, they are for molecules key to targeting H.I.V. 'mRNA is just this miraculous — I really do think miraculous — tool to deliver things that you want into places that were not possible before,' said Dr. Sharon Lewin, director of the Cumming Global Center for Pandemic Therapeutics in Melbourne, who led the study. Vaccines deploying mRNA instruct the body to produce a fragment of the virus, which then sets off the body's immune response. In the United States, the shots were initially hailed for turning back the pandemic, then viewed by some with suspicion and fear. Some officials, including Health Secretary Robert F. Kennedy Jr., have falsely said that they are highly dangerous and even deadly. Last week, the Department of Health and Human Services sought to limit the vaccine's availability to pregnant women, children and healthy younger adults. The administration also canceled a nearly $600 million contract with the drugmaker Moderna to develop an mRNA shot for humans against bird flu. Want all of The Times? Subscribe.

Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance
Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance

Associated Press

timean hour ago

  • Associated Press

Who's in charge? CDC's leadership 'crisis' apparent amid new COVID-19 vaccine guidance

WASHINGTON (AP) — There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a 58-second video that the government would no longer endorse the COVID-19 vaccine for healthy children or pregnant women. The director of the Centers for Disease Control and Prevention — the person who typically signs off on federal vaccine recommendations — was nowhere to be seen. The CDC, a $9.2 billion-a-year agency tasked with reviewing life-saving vaccines, monitoring diseases and watching for budding threats to Americans' health, is without a clear leader. 'I've been disappointed that we haven't had an aggressive director since — February, March, April, May — fighting for the resources that CDC needs,' said Dr. Robert Redfield, who served as CDC director under the first Trump administration and supported Kennedy's nomination as the nation's health secretary. $9.2 billion-a-year agency without leader as nomination awaits The leadership vacuum at a foremost federal public health agency has existed for months, after President Donald Trump suddenly withdrew his first pick for CDC director in March. A hearing for his new nominee — the agency's former acting director Susan Monarez — has not been scheduled because she has not submitted all the paperwork necessary to proceed, according to a spokesman for Sen. Bill Cassidy, R-La., who will oversee the nomination. HHS did not answer written questions about Monarez's nomination, her current role at the CDC or her salary. An employee directory lists Monarez, a longtime government employee, as a staffer for the NIH under the Advanced Research Projects Agency for Health. Redfield described Kennedy as 'very supportive' of Monarez's nomination. Instead, a lawyer and political appointee with no medical experience is 'carrying out some of the duties' of director at the agency that for seven decades has been led by someone with a medical degree. Matthew Buzzelli, who is also the chief of staff at the CDC, is 'surrounded by highly qualified medical professionals and advisors to help fulfill these duties as appropriate,' Andrew Nixon, an HHS spokesperson said in a statement. Adding to the confusion was an employee-wide email sent last week that thanked 'new acting directors who shave stepped up to the plate.' The email, signed by Monarez, listed her as the acting director. It was was sent just days after Kennedy said at a Senate hearing that Monarez had been replaced by Buzzelli. The lack of a confirmed director will be a problem if a public health emergency such as the COVID-19 pandemic or a rapid uptick in measles cases hits, said Michael Osterholm, an epidemiologist at the University of Minnesota. 'CDC is a crisis, waiting for a crisis to happen,' said Osterholm. 'At this point, I couldn't tell you for the life of me who was going to pull what trigger in a crisis situation.' An acting director rarely seen, and stalled decisions At CDC headquarters in Atlanta, employees say Monarez was rarely heard from between late January – when she was appointed acting director – and late March, when Trump nominated her. She also has not held any of the 'all hands' meetings that were customary under previous CDC chiefs, according to several staffers. One employee, who insisted on anonymity because they were not authorized to speak to the media and fears being fired if identified said Monarez has been almost invisible since her nomination, adding that her absence has been cited by other leaders as an excuse for delaying action. The situation already has led to confusion. In April, a 15-member CDC advisory panel of outside experts met to discuss vaccine policy. The panel makes recommendations to the CDC Director, who routinely signs off on them. But it was unclear during the meeting who would be reviewing the panel's recommendations, which included the expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. HHS officials said the recommendations were going to Buzzelli, but then weeks passed with no decision. A month after the meeting ended, the CDC posted on a web site that Kennedy had signed off on recommendations for travelers against chikungunya, a viral disease transmitted to humans by mosquitos. But there continues to be no word about a decision about the other vaccine recommendations. Controversial COVID-19 vaccine recommendations bypassed CDC panel The problem was accentuated again last week, when Kennedy rolled out recommendations for the COVID-19 vaccine saying they were no longer recommended for healthy children or pregnant women, even though expectant mothers are considered a high-risk group if they contract the virus. Kennedy made the surprise announcement without input from the CDC advisory panel that has historically made recommendations on the nation's vaccine schedule. The CDC days later posted revised guidance that said healthy kids and pregnant women may get the shots. Nixon, the HHS spokesman, said CDC staff were consulted on the recommendations, but would not provide staffer's names or titles. He also did not provide the specific data or research that Kennedy reviewed to reach his conclusion on the new COVID-19 recommendations, just weeks after he said that he did not think 'people should be taking medical advice' from him. 'As Secretary Kennedy said, there is a clear lack of data to support the repeat booster strategy in children,' Nixon said in a statement. Research shows that pregnant women are at higher risk of severe illness, mechanical ventilation and death, when they contract COVID-19 infections. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. Vaccinations also have been recommended for pregnant women because it passes immunity to newborns who are too young for vaccines and also vulnerable to infections. Nixon did not address a written question about recommendations for pregnant women. Kennedy's decision to bypass the the advisory panel and announce new COVID-19 recommendations on his own prompted a key CDC official who works with the committee – Dr. Lakshmi Panagiotakopoulos – to announce her resignation last Friday. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in an email seen by an Associated Press reporter. Signs are mounting that the CDC has been 'sidelined' from key decision-making under Kennedy's watch, said Dr. Anand Parekh, the chief medical adviser for The Bipartisan Policy Center. 'It's difficult to ascertain how we will reverse the chronic disease epidemic or be prepared for myriad public health emergencies without a strong CDC and visible, empowered director,' Parekh said. 'It's also worth noting that every community in the country is served by a local or state public health department that depends on the scientific expertise of the CDC and the leadership of the CDC director.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store